SZSayid Shafi Zuhur

Sayid Shafi Zuhur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sayid Shafi Zuhur has a total of 120 co-authors. Here are the top co-authors by number of shared publications:

  • Yuksel Altuntas

    Department of Endocrinology and Metabolism, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

    16 shared publications
  • Gulsah Elbuken

    Department of Endocrinology and Metabolism, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey

    11 shared publications
  • Idris Kuzu

    Endocrinology and Metabolism Clinic, Nigde Government Hospital, Nigde, Turkey

    9 shared publications
  • Birol Topcu

    Department of biostatistics, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey

    7 shared publications
  • Gulhan Akbaba

    Department of Endocrinology and Metabolism, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey

    7 shared publications
  • Selvinaz Erol

    Department of Endocrinology and Metabolism, University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

    7 shared publications

Latest Publications

  • Open Access

    Dermatological manifestations of hypoparathyroidism: a multicenter study

    by Hilal Kaya Erdoğan, Filiz Cebeci Kahraman, İsA An, Nurşad Çifçi, Hülya Albayrak, Mustafa Esen, Arzu Kılıç, Göknur Yorulmaz, Murat Cinel, Seda Erem Basmaz, et al.

  • Postoperative frequency of normocalcemic elevated parathormone in patients surgically treated for primary hyperparathyroidism: A single-center experience

    by Gülşah Elbüken, Ogün İrEm Bilen, Beyza Olcay Öztürk, Hünkar Ağgül, Sibel Özkan-Gürdal, Burcu Tokuç, Sayid Shafi Zuhur

    Aim: After parathyroidectomy, parathormone levels may remain elevated despite normalization of serum calcium levels in some patients, which is known as “postoperative normocalcemic elevated parathormone”. In this study, we aimed to determine postoperative normocalcemic elevated parathormone frequency in patients undergoing parathyroidectomy due to primary hyperparathyroidism through a retrospective review.Material and Methods: Preoperative, intraoperative, early postoperative (maximum 7-days, starting from the next day of surgery until discharge) and late postoperative (months 1, 3, 6 and 12) laboratory tests of the 127 patients were reviewed retrospectively. Corrected calcium levels were obtained using serum albumin levels.Results: Laboratory values consistent with postoperative normocalcemic elevated parathormone were identified in 56%, 44%, 42.3% and 31.9% of the patients at 1, 3, 6 and 12 months postoperatively. There are missing data in the 127 patients who underwent surgery because some patients did not attend their follow-up visits or were followed up in other centers. Serum calcium values were available and within normal range for all 91 patients followed for a mean duration of 44.0±27.2 months (median= 36, min= 15, max=144). The frequency of postoperative normocalcemic elevated parathormone was 34.4% among patients with serum calcium and PTH measurements available from the last visit. Conclusion: The prevalence of postoperative normocalcemic elevated parathormone varies among different patient series depending on the criteria used. Whether the underlying secondary hyperparathyroidism contributes to postoperative normocalcemic elevated parathormone should be investigated and managed appropriately. Considering that postoperative normocalcemic elevated parathormone may also represent primary hyperparathyroidism recurrence, regular follow-up is required for patients.

  • The impact of microscopic extrathyroidal extension on the prognosis of medullary thyroid carcinoma: A multicenter cohort study

    by Beyza Olcay Ozturk, Umran Keskin, Serhat Uysal, Aysa Hacioglu, Seda Karsli, Burak Andac, Umit Nur Ozbay, Hulyanur Sodan, Sebnem Burhan, Coskun Ates, et al.

  • Disease-free survival and the prognostic factors affecting disease-free survival in patients with medullary thyroid carcinoma: a multicenter cohort study

    by Sayid Shafi Zuhur, Beyza Olcay Ozturk, Umran Keskin, Serhat Uysal, Aysa Hacioglu, Ugur Avci, Seda Karsli, Burak Andac, Umit Nur Ozbay, Faruk Kilinc, et al.

    Purpose Despite several factors that may have been associated with poor disease-free survival (DFS) in patients with medullary thyroid carcinoma (MTC), only a few studies have evaluated the prognostic factors affecting DFS in MTC patients. Therefore, this study evaluated the prognostic factors affecting DFS, in a large number of patients with MTC. Methods Patients treated for MTC were retrospectively analyzed. Patients were stratified as having persistent/recurrent disease and no evidence of disease (NOD) at the last follow-up. The factors affecting DFS after the initial therapy and during the follow-up period were investigated. Results This study comprised 257 patients [females 160 (62.3%), hereditary disease 48 (18.7%), with a mean follow-up time of 66.8 ± 48.5 months]. Persistent/recurrent disease and NOD were observed in 131 (51%) and 126 (49%) patients, respectively. In multivariate analysis, age > 55 (HR: 1.65, p = 0.033), distant metastasis (HR: 2.41, p = 0.035), CTN doubling time (HR: 2.7, p = 0.031), and stage III vs. stage II disease (HR 3.02, p = 0.048) were independent predictors of persistent/recurrent disease. Although 9 (8%) patients with an excellent response after the initial therapy experienced a structural recurrence, the absence of an excellent response was the strongest predictor of persistent/recurrent disease (HR: 5.74, p < 0.001). Conclusions The absence of an excellent response after initial therapy is the strongest predictor of a worse DFS. However, a significant proportion of patients who achieve an excellent response could experience a structural recurrence. Therefore, careful follow-up of patients, including those achieving an excellent response is essential.


  • The impact of microscopic extrathyroidal extension on the clinical outcome of classic subtype papillary thyroid microcarcinoma: a multicenter study

    by Sayid Shafi Zuhur, Hunkar Aggul, Ugur Avci, Selvinaz Erol, Mazhar Muslum Tuna, Serhat Uysal, Gulhan Akbaba, Faruk Kilinc, Merve Catak, Sakin Tekin, et al.

    Objectives Despite the presumed overdiagnosis of papillary thyroid microcarcinoma (PTMC) which has resulted in a new trend toward less-extensive surgery and a preference for active surveillance, the impact of microscopic extrathyroidal extension (mETE) on the clinical outcomes of PTMC is still controversial. This study assessed the impact of mETE on the clinical outcomes of patients with classic subtype PTMC. Methods The data of consecutive patients who underwent thyroidectomy and were histopathologically diagnosed as classic subtype PTMC were analyzed. Cox’s proportional hazards model was used to assess the impact of contributing variables on persistent/recurrent disease. Disease-free survival was estimated using the Kaplan-Meier method. Results This study included 1013 patients (84% females), with a mean follow-up period of 62.5 ± 35.3 months. Patients with mETE had a significantly higher rate of locoregional persistent/recurrent disease than patients without mETE (9.8% vs 2.1%, p < 0.001). The disease-free survival rate was significantly lower in patients with mETE than in those without (90.2% vs 97%, Log-Rank p < 0.001). Furthermore, mETE and neck lymph node involvement were independent predictors of persistent/recurrent disease in multivariate analysis (HR: 2.43, 95% CI:1.02–5.81, p = 0.043; HR: 4.38, 95% CI: 1.7–11.2, p = 0.002, respectively). Conclusions In patients with the classic subtype of PTMC, mETE is an independent predictor of persistent/recurrent disease and is associated with a lower DFS rate. However, neck lymph node involvement is the strongest predictor of persistent/recurrent disease. Therefore, PTMCs with mETE and neck lymph node involvement are at a higher risk of persistent/recurrent disease than individuals lacking both characteristics.


  • Do Histologically Aggressive Subtypes of Papillary Thyroid Microcarcinoma have Worse Clinical Outcome than Non-Aggressive Papillary Thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study

    by Sayid Shafi Zuhur, Hunkar Aggul, Ugur Avci, Selvinaz Erol, Mazhar Müslüm Tuna, Serhat Uysal, Gulhan Akbaba, Faruk Kilinç, Merve Catak, Sakin Tekin, et al.

    Histologically aggressive micropapillary thyroid carcinomas (PTMC) subtypes are thought to be associated with an aggressive clinical course. However, evidence for unfavorable clinical outcomes in patients with aggressive PTMC subtypes is not clear. In this study, we intended to determine the difference in clinical outcomes between patients with aggressive and non-aggressive PTMC subtypes. In this multicenter cohort study, the computer-recorded clinical and histopathological data of patients who underwent thyroid surgery between January 2000 - January 2021 in 9 referral centers and were diagnosed as PTMC were analyzed. A total of 1585 patients [female 1340 (84.5%), male 245 (15.5%), mean age 47.9±11.63 years), with a mean follow-up time of 66.55±37.16 months], were included in the study. Ninety-eight cases were diagnosed as aggressive and 1487 as non-aggressive subtypes. Persistent/recurrent disease was observed in 33 (33.7% )and 41 (2.8%) patients with aggressive and non-aggressive subtypes (p<0.001). Diseases-free survival rates were markedly lower in patients with aggressive than in those with non-aggressive PTMC subtypes (66.3 vs. 94.8%, log-rank p<0.001). Moreover, in multivariate analysis, aggressive histology was an independent predictor of persistent/recurrent disease, after controlling for other contributing factors (HR 5.78, 95% CI 3.32–10, p<0.001). Patients with aggressive PTMC subtypes had higher rates of incomplete biochemical and structural response than patients with non-aggressive subtypes as well (p1 cm in size. Therefore, the histopathological subtype of PTMC should be taken into consideration to tailor a personalized management plan.


  • The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves’ hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves’ hyperthyroidism

    by Sayid Shafi Zuhur, Ogun Bilen, Hunkar Aggul, Birol Topcu, Aliye Celikkol, Gulsah Elbuken

    Introduction: Although the TSH-receptor antibody (TRAb) plays a central role in the pathogenesis of Graves’ disease (GD), the association between TRAb at first diagnosis and clinical and laboratory parameters is not well known. On the other hand, a minority of patients with GD may be TRAb negative, and there is a lack of adequate evidence to demonstrate the clinical and laboratory characteristics of these patients. Therefore, we aimed to investigate the association of TRAb at the initial diagnosis of GD with the clinical and laboratory parameters in a large number of patients with GD and to compare the clinical and laboratory parameters between patients with high TRAb levels and TRAb negative patients. Material and methods: This study included 440 patients [326 (74%) female, 114 (26%) make]. All patients were classified according to gender, age, smoking habit, and TRAb level. Results: TRAb levels were significantly higher in male compared to female patients and in smokers compared to non smokers. Smoking male patients had the highest TRAb levels. In regression analysis, goitre size, male gender, cigarette smoking, Graves’ orbitopathy, fT3, and anti-TPO antibody levels were independently associated with high TRAb levels, while age at diagnosis and fT4 levels were not independently associated with high TRAb levels. TRAb-negative GD was diagnosed in 80 (18%) patients. TRA-negative patients had markedly less severe clinical and laboratory hyperthyroidism compared to patients with high TRAb levels. Moreover, the smoking habit was significantly lower in patients with TRAb negative GD. Conclusions: According to our study results, TRAb levels at the initial diagnosis of GD are differently associated with clinical and laboratory parameters. Male patients and smoking patients with GD tended to have markedly higher TRAb levels and more severe clinical hyperthyroidism. Therefore, besides other contributing factors, male gender and smoking may affect TRAb levels and consequently the severity of hyperthyroidism in patients with GD. Furthermore, male gender and smoking may have a synergistic effect on TRAb levels and consequently on the severity of hyperthyroidism in patients with GD. Introduction: Although the TSH-receptor antibody (TRAb) plays a central role in the pathogenesis of Graves’ disease (GD), the association between TRAb at first diagnosis and clinical and laboratory parameters is not well known. On the other hand, a minority of patients with GD may be TRAb negative, and there is a lack of adequate evidence to demonstrate the clinical and laboratory characteristics of these patients. Therefore, we aimed to investigate the association of TRAb at the initial diagnosis of GD with the clinical and laboratory parameters in a large number of patients with GD and to compare the clinical and laboratory parameters between patients with high TRAb levels and TRAb negative patients. Material and methods: This study included 440 patients [326 (74%) female, 114 (26%) make]. All patients were classified according to gender, age, smoking habit, and TRAb level. Results: TRAb levels were significantly higher in male compared to female patients and in smokers compared to non smokers. Smoking male patients had the highest TRAb levels. In regression analysis, goitre size, male gender, cigarette smoking, Graves’ orbitopathy, fT3, and anti-TPO antibody levels were independently associated with high TRAb levels, while age at diagnosis and fT4 levels were not independently associated with high TRAb levels. TRAb-negative GD was diagnosed in 80 (18%) patients. TRA-negative patients had markedly less severe clinical and laboratory hyperthyroidism compared to patients with high TRAb levels. Moreover, the smoking habit was significantly lower in patients with TRAb negative GD. Conclusions: According to our study results, TRAb levels at the initial diagnosis of GD are differently associated with clinical and laboratory parameters. Male patients and smoking patients with GD tended to have markedly higher TRAb levels and more severe clinical hyperthyroidism. Therefore, besides other contributing factors, male gender and smoking may affect TRAb levels and consequently the severity of hyperthyroidism in patients with GD. Furthermore, male gender and smoking may have a synergistic effect on TRAb levels and consequently on the severity of hyperthyroidism in patients with GD.


  • Open Access

    Diabetes Risk Assessment and Awareness In a University Academics and Employees

    by Tulin Yildiz, Senay Zuhur, Sayid Shafi Zuhur

    The Medical Bulletin of Sisli Etfal Hospital


  • Open Access

    Adrenal İnsidentalomalarda Fonksiyonellik ve Büyüme Oranlarının Değerlendirilmesi: Tek Merkez Deneyimi

    by Suna Avci, Yüksel Aslı OZTURKMEN, Sayid Zuhur, Gulkan Ozkan, Elif Guven, Nazan Demi̇r, Yuksel Altuntas

    En tr Objectives: In this study, we aimed to transfer observational data on incidentaloma cases, which we encountered in our center, in terms of their radiological, histopathologic features and hormonal activities, retrospectively review the growth rates during follow-up. Material and Method: In this retrospective study 137 incidentaloma cases that met the inclusion criteria were analyzed. The medical records of all cases were analyzed statistically by recording age, sex information, hormonal examinations and imaging results, functional status of masses, histopathological findings, and information on adrenal mass diameter change during follow-up. Results: In this study, 97 (71%) patients were female and 40 (29%) were male. 99 patients (72.3%) were diagnosed with nonfunctional adenomas (NFA), 21 patients (15%) with subclinical Cushing syndrome (SCS), 9 patients (6%) with pheochromocytoma, 6 patients (4%) with hyperaldosteronism, and 2 patients (1%) with congenital adrenal hyperplasia (CAH). Patients with functional masses were significantly younger than patients with NFA (p: 0.04). Malignancy was identified in 6 patients (4%). The mean follow-up period of the patients was 20.2 ± 19.86 months. Growth in mass size was detected in 24 patients (17%). In 6 of the masses (26% of the growing masses, 4% of all the masses), growth of over 1 cm was observed. The growth rate of the masses in male patients was significantly higher than the growth rate in female patients (p: 0.031). Conclusion: The incidence of mass growth and malignancy was higher in older age and male sex. Patient’s age and sex should be bear in mind for their duration and frequency of follow-up in terms of functionality and malignant conversion. Amaç: Bu çalışmada merkezimizde karşılaştığımız insidentaloma vakalarının radyolojik, histopatolojik özellikleri ve hormonal aktiviteleri yönünden gözlemsel verilerini aktarmayı, takipleri esnasında büyüme oranlarını retrospektif olarak incelemeyi amaçladık. Gereç ve Yöntem: Dahil edilme kriterlerine uyan 137 insidentaloma vakaları retrospektif olarak incelendi. Tüm olguların medikal kayıtlarından yaş, cinsiyet bilgileri, hormonal tetkik ve görüntüleme sonuçları, kitlelerin fonksiyonellik durumları, histopatolojik bulguları ve takipleri boyunca adrenal kitle çapındaki değişim bilgileri kaydedilerek istatistiksel yöntemlerle analiz edildi. Bulgular: Hastaların 97’si (%71) kadın, 40’ı (%29) erkek idi. 99 (%72.3) hastaya nonfonksiyonel adenom (NFA), 21 (%15) hastaya subklinik Cushing sendromu (SCS), 9 (%6) hastaya feokromasitoma, 6 (%4) hastaya hiperaldosteronizm, 2 (%1) hastaya konjenital adrenal hiperplazi (KAH) tanısı koyuldu. Fonksiyonel kitleye sahip olan hastalar anlamlı olarak daha genç saptandı (p:0,04). 6 (%4) hastada malignite saptandı. Hastaların ortalama takip süresi 20.2±19.86 ay idi. Takipler sırasında 24 hastada (%17) kitle boyutunda büyüme saptandı. Kitlelerin 6’sında (büyüyen kitlelerin %26, tüm kitlelerin %4 ü) 1 cm üzerinde büyüme görüldü. Erkek hastalardaki kitlelerin büyüme miktarı, kadın hastaların kitlelerdeki büyüme miktarından anlamlı olarak daha yüksekti (p:0.031). Sonuç: Kitle büyüme miktarı ve malignite görülme sıklığı ileri yaş ve erkek cinsiyette daha fazla saptanmıştır. İnsidentalomaların fonksiyonellik ve malign dönüşüm açısından takibinde hastaların yaşı ve cinsiyeti göz önünde bulundurulmalıdır.